HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LKFT
Lakefront Biotherapeutics N.V.
LKFT's fundamentals are strong: revenue more than tripled and its operating margin went from −127% to 62%, though free cash flow turned negative. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LKFT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
LKFT's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LKFT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.2x | $32.15 | -5.2% |
| Current | 3.4x | $33.93 | — |
| Fair | 3.5x | $35.61 | +5% |
| Expensive | 5.1x | $51.37 | +51% |
Historical ranges are pointers, not guarantees.
LKFT's PE is 3.4x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LKFT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect LKFT's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
LKFT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2023 | -$0.67 | +$0.54 |
| Q3 2023 | -$0.72 | -820% |
| Q2 2023 | -$0.79 | +$0.58 |
LKFT has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LKFT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over LKFT on profitability, with a higher operating margin.
LKFT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.5M | -81% |
| Q1 2026 | $7.2M | -91% |
| Q4 2025 | $1B | +1093% |
| Q3 2025 | $79.1M | +19% |
| Q2 2025 | $72.5M | -16% |
| Q1 2025 | $83.3M | +20% |
| Q3 2024 | $66.5M | -50% |
| Q2 2024 | $86.5M | +30% |
LKFT's revenue is growing: $13M last quarter, down 81% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -359% | -272 points |
| Q1 2026 | -983% | -771 points |
| Q4 2025 | 84% | +192 points |
| Q3 2025 | -59% | +32 points |
| Q2 2025 | -87% | -38 points |
| Q1 2025 | -212% | -159 points |
| Q4 2024 | -107% | N/A |
| Q3 2024 | -91% | -66 points |
LKFT's operating margin was −359% last quarter, down 272 points from the same quarter a year ago, near the bottom of its range since 2017.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
LKFT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$125.5M |
| Q4 2020 | -$278.6M | -108% |
| Q4 2019 | $3.7B | +$3.8B |
| Q4 2018 | -$65.1M | +$104.2M |
LKFT has burned cash in most quarters: −$219M over the past year, against $3.2B the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LKFT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LKFT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.4% | +4.2M shares |
| 1 year | +6.4% | +4.2M shares |
| 3 years | +6.5% | +4.3M shares |
LKFT has 70M diluted shares, up 6.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
LKFT hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over LKFT on leverage, with a lower net debt burden relative to earnings.
LKFT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
LKFT has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LKFT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 87.8 | Overbought |
LKFT's weekly RSI is 69 (neutral) and its Stochastic is 88 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LKFT PE vs Healthcare Sector
| Metric | LKFT | Sector median | Relative |
|---|---|---|---|
| PE | 3.4x | 26x | 87% below |
| PE % | 39 | 29 | 10 pts above |
LKFT is trading at 3.4x earnings, a 87% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LKFT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 8.7% above |
| 20 week MA | $29.6 | 15% above |
| 50 week MA | $30.4 | 12% above |
| 100 week MA | $29.6 | 15% above |
| 200 week MA | $32.2 | 5.5% above |
LKFT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
LKFT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $209.4 | $99.3 | -53% |
| 2021 | $99.3 | $55.9 | -44% |
| 2022 | $55.9 | $42.2 | -25% |
| 2023 | $42.2 | $40.7 | -3.7% |
| 2024 | $40.7 | $27.3 | -33% |
| 2025 | $27.3 | $33.0 | +21% |
| 2026 YTD | $33.0 | $33.9 | +2.7% |
LKFT has the edge over HIMS on returns for 2026, with the stronger performance.